Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss
A legfontosabb adatok
- Ki végzi
- The Affiliated Hospital of Qingdao University
- Hol
- Chongqing, Guangzhou, Qingdao és Tai’an (Kína)Mind a 5 helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 1/2. fázis
- Résztvevők
- 9 fő, tervezett
- Kezdés
- 2026. febr. 28.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 5 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at low doses
- Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at moderate doses
- Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at high doses
- Standard treatment for sudden deafness+hUC-MSC-sEV-003 at an appropriate dose as determined by stage I trial
- Standard treatment for sudden deafness+dexamethasone
- A regiszteradat frissítve
- 2026. március 25.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with sudden, severe or profound hearing loss in one ear. It tests ear-drum injections of small extracellular vesicles (tiny particles made from stem cells).
- Életkor
- 18 to 65 years
- Nem
- Men and women
- A betegség stádiuma
- Sudden hearing loss in one ear that came on within 72 hours. Hearing dropped by at least 30 decibels in at least 3 frequency ranges compared to the healthy ear. Average pure tone threshold is ≥ 65 decibels. You must join within 7 days after the hearing loss started.
- Korábbi kezelés
- No treatment at any other hospital and no medicine taken on your own for this hearing loss. No steroid treatment for any reason within the past 30 days.
A részvétel fő kizáró okai
- Pregnant or breastfeeding women
- Past chronic ear disease, ear surgery, autoimmune hearing loss or Meniere's syndrome
- Autoimmune diseases or chronic inflammatory diseases
- Severe liver or kidney damage
- Past bleeding in the brain, or currently taking blood thinners (anticoagulants)
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- Sudden unilateral hearing loss that occurs within 72 hours, with a decrease of at least 30 decibels in at least 3 frequency ranges compared to the healthy ear, and an average pure tone threshold of ≥ 65 decibels
- Enrollment must be completed within 7 days after the onset of sudden deafness
- Men or women aged 18 to 65
- Not treated in any other hospital and not taking any treatment medication on one's own
- Be able to understand the trial protocol and undergo regular follow-up visits and check-ups
Ki nem vehet részt
- Having received steroid treatment for any reason within the past 30 days
- Patients with a previous history of cerebral hemorrhage or those currently taking anticoagulant medications
- With a history of chronic ear diseases, ear surgery, autoimmune hearing loss or a confirmed diagnosis of Meniere's syndrome in the past
- There are autoimmune diseases or chronic inflammatory diseases
- Pregnant or lactating women
- Severe damage to liver and kidney functions
- Other cases in which the researchers judged the candidates to be unsuitable for inclusion
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Helyszínek itt: Kína
- Chongqing General HospitalChongqing, KínaContact: Wei YuanToborzás még nem indult
- Guangdong General HospitalGuangzhou, KínaContact: Hao XiongToborzás még nem indult
- the First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, KínaContact: Qingling FuToborzás még nem indult
- The Affiliated Hospital of Qingdao UniversityQingdao, KínaContact: Yan JiangToborzás még nem indult
- he Second Affiliated Hospital of Shandong First Medical UniversityTai’an, KínaContact: Deli WangToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn if small extracellular vesicles derived from mesenchymal stem cells work to treat severe and above sudden sensorineural hearing loss. It will also learn about the safety of small extracellular vesicles. The main questions it aims to answer are:
A teljes eredeti leírásKevesebb
1. Does small extracellular vesicles combined with traditional drug treatment improve hearing even better in severe and above sudden deafness participants? 2. What medical problems do participants have with intratympanic injection of small extracellular vesicles? Researchers will compare small extracellular vesicles to dexamethasone to see if small extracellular vesicles work to treat severe and above sudden sensorineural hearing loss.
In clinical Phase I trial, the investigators will complete the safety check and dose exploration.
Participants will:
1. Receive traditional drug treatment in accordance with the "Guidelines for the Diagnosis and Treatment of Sudden Deafness (2015) 2. Receive small extracellular vesicles or a placebo tympanic injection additionally 3. Visit the clinic once every 2 weeks for checkups and tests 4. Receive tympanic injections of small extracellular vesicles ranging from low concentration to high concentration 5. Be evaluated for any adverse reactions In clinical Phase II trial, participants were randomly divided into a control group and an experimental group.
Participants will: 6. Received intratympanic injections of small extracellular vesicles 3 times together with traditional drug treatment in experimental group 7. Received intratympanic injections of 5mg dexamethasone 3 times together with traditional drug treatment in control group, also for a total of 3 times Visit the clinic once 7 days , 1month and 3 months after treatment for checkups and tests of pure tone audiometry, speech audiometry, tinnitus disability scale and visual analogue scale assessment
A vizsgálat 5 csoportja
- Low-dose Treatment group-Clinical Phase IA vizsgált kezelés
Standard treatment for sudden deafness+hUC-MSC-sEV-003 at low-dose treatment in clinical phase I
Kezelés: Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at low doses
- Moderate-dose Treatment Group--Clinical Phase IA vizsgált kezelés
Standard treatment for sudden deafness+hUC-MSC-sEV-003 at moderate-dose treatment in clincal phase I
Kezelés: Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at moderate doses
- High-dose treatment in Clincal Phase IA vizsgált kezelés
Standard treatment for sudden deafness+hUC-MSC-sEV-003 at high-dose treatment in clincal phase I
Kezelés: Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at high doses
- Treatment Group--Clinical Phase IIA vizsgált kezelés
Standard treatment for sudden deafness+hUC-MSC-sEV-003 at an appropriate dose as determined by the stage I trial
Kezelés: Standard treatment for sudden deafness+hUC-MSC-sEV-003 at an appropriate dose as determined by stage I trial
- Control Group--Clinical Phase IIMár használt kezelés, összehasonlításként
Standard treatment for sudden deafness+dexamethasone injected into the tympanic cavity
Kezelés: Standard treatment for sudden deafness+dexamethasone
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Clinical Phase I and IIa Trials of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07404709: ki vehet részt
- A regiszteradat frissítve
- 2026. március 25.